Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abeona Therapeutics (ABEO) Other Accumulated Expenses (2021 - 2025)

Abeona Therapeutics (ABEO) has 5 years of Other Accumulated Expenses data on record, last reported at $35000.0 in Q3 2025.

  • For Q3 2025, Other Accumulated Expenses rose 3400.0% year-over-year to $35000.0; the TTM value through Sep 2025 reached $35000.0, up 3400.0%, while the annual FY2024 figure was $64000.0, 6300.0% up from the prior year.
  • Other Accumulated Expenses reached $35000.0 in Q3 2025 per ABEO's latest filing, down from $80000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $317000.0 in Q1 2025 and bottomed at $1000.0 in Q4 2023.
  • Average Other Accumulated Expenses over 5 years is $123769.2, with a median of $80000.0 recorded in 2025.
  • Peak YoY movement for Other Accumulated Expenses: tumbled 99.51% in 2024, then surged 31600.0% in 2025.
  • A 5-year view of Other Accumulated Expenses shows it stood at $296000.0 in 2021, then tumbled by 31.08% to $204000.0 in 2022, then crashed by 99.51% to $1000.0 in 2023, then surged by 6300.0% to $64000.0 in 2024, then plummeted by 45.31% to $35000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Other Accumulated Expenses were $35000.0 in Q3 2025, $80000.0 in Q2 2025, and $317000.0 in Q1 2025.